- Home
- PRQR vs SLN Comparison
PRQR vs SLN Comparison
Compare PRQR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- SLN
- Stock Information
- Founded
- PRQR 2012
- SLN 1994
- Country
- PRQR Netherlands
- SLN United Kingdom
- Employees
- PRQR N/A
- SLN N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- SLN Health Care
- Exchange
- PRQR Nasdaq
- SLN Nasdaq
- Market Cap
- PRQR 224.4M
- SLN 268.8M
- IPO Year
- PRQR 2014
- SLN N/A
- Fundamental
- Price
- PRQR $2.80
- SLN $7.37
- Analyst Decision
- PRQR Strong Buy
- SLN Buy
- Analyst Count
- PRQR 8
- SLN 6
- Target Price
- PRQR $8.88
- SLN $39.67
- AVG Volume (30 Days)
- PRQR 649.8K
- SLN 177.0K
- Earning Date
- PRQR 11-07-2025
- SLN 11-13-2025
- Dividend Yield
- PRQR N/A
- SLN N/A
- EPS Growth
- PRQR N/A
- SLN N/A
- EPS
- PRQR N/A
- SLN N/A
- Revenue
- PRQR $20,129,184.00
- SLN $27,169,000.00
- Revenue This Year
- PRQR N/A
- SLN N/A
- Revenue Next Year
- PRQR N/A
- SLN N/A
- P/E Ratio
- PRQR N/A
- SLN N/A
- Revenue Growth
- PRQR 8.65
- SLN 22.28
- 52 Week Low
- PRQR $1.07
- SLN $1.97
- 52 Week High
- PRQR $4.21
- SLN $18.32
- Technical
- Relative Strength Index (RSI)
- PRQR 60.30
- SLN 68.80
- Support Level
- PRQR $2.71
- SLN $6.92
- Resistance Level
- PRQR $3.00
- SLN $7.75
- Average True Range (ATR)
- PRQR 0.24
- SLN 0.53
- MACD
- PRQR 0.01
- SLN 0.11
- Stochastic Oscillator
- PRQR 71.11
- SLN 85.35
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.